Levetiracetam Ratiopharm

Levetiracetam, the active ingredient in Levetiracetam Ratiopharm, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial seizures, generalized tonic‑clonic seizures, and myoclonic seizures, helping to reduce seizure frequency in individuals diagnosed with epilepsy.

GNH USA supplies Levetiracetam Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics across global markets while adhering to stringent quality and regulatory standards. Our distribution network ensures reliable delivery and compliance with local import requirements.

Levetiracetam is an anticonvulsant used to manage seizure disorders within the epileptic disease spectrum.

- Partial seizures: Reduces frequency of focal onset seizures in patients with epilepsy. - Generalized tonic‑clonic seizures: Controls bilateral convulsive episodes and lowers recurrence. - Myoclonic seizures: Diminishes rapid, brief muscle jerks associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or low in energy. - Headache: mild to moderate cranial pain. - Irritability: increased emotional sensitivity or agitation. - Nausea: upset stomach or urge to vomit. - Nasal congestion: blocked or runny nose.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood changes: depression, suicidal thoughts, or severe anxiety. - Blood disorders: thrombocytopenia or leukopenia. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Multiorgan hypersensitivity: systemic rash with fever and organ involvement.

When prescribing Levetiracetam, clinicians should consider several safety considerations to minimize risk.

- Renal function: Adjust dose in patients with impaired kidney function. - Psychiatric history: Monitor for mood alterations or suicidal ideation. - Concomitant CNS depressants: Use caution with other sedating agents. - Pregnancy status: Evaluate risk‑benefit as safety data are limited. - Driving and operating machinery: Advise patients about possible dizziness or drowsiness. - Store at ambient temperature: Keep tablets in the original container, protect from moisture and light.

Levetiracetam can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: May reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: Potential to lower levetiracetam concentrations, risking breakthrough seizures.

Moderate Interactions (Monitor Closely): - Valproic acid: May increase levetiracetam levels, requiring observation for side effects. - Alcohol: Combined use can enhance central nervous system depression. - Other antiepileptic drugs: May require dose adjustments based on therapeutic monitoring.